linsitinib

Phase 2Small molecule

linsitinib is one of 219 small molecule programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

218

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous Squamous Cell CarcinomaActive, not recruiting

Ewing SarcomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Gastrointestinal Stromal TumorActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Thyroid Eye DiseaseActive, not recruiting

Cutaneous Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Ewing SarcomaPhase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Gastrointestinal Stromal TumorPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

Thyroid Eye DiseasePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

598 competitors in Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

33 2

Tarlatamab-Dznl

Amgen

Phase 3

10 3

Zepzelca

Jazz Pharmaceuticals

Phase 3

10 4

Lenvima

Eisai

Phase 3

5 5

Camptosar

EEastern Cooperative Oncology Group

Phase 3

13 6

Ellence

Merck & Co.

Phase 3

2 7

Ifex

BBaxter Healthcare Corporation

Phase 3

5 8

Etopophos

GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH

Phase 3

3 9

Mesnex

BBaxter Healthcare Corporation

Phase 3

1 10

Tiragolumab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2/3Active, not recruiting

Thyroid Eye Disease

NCT05276063

Clinical

Trials by Indication[1]

Thyroid Eye Disease2 trials

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Recruiting·SSling Therapeutics, Inc.·Phase 2/3·NCT06112340·75 enrolled

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Active, not recruiting·SSling Therapeutics, Inc.·Phase 2/3·NCT05276063·90 enrolled

Trial1 trial

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Completed· Astellas logo

Astellas·Phase 2·NCT02057380·13 enrolled

Metastatic Prostate Cancer1 trial

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01533246·17 enrolled

Cutaneous Squamous Cell Carcinoma1 trial

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Withdrawn·OOHSU Knight Cancer Institute·Phase 1/2·NCT01465815

Small Cell Lung Cancer1 trial

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01533181·44 enrolled

2 more indications

Gastrointestinal Stromal Tumor1 trial

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01560260·20 enrolled

Ewing sarcoma1 trial

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Completed·UUniversity of Oxford·Phase 2·NCT02546544·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for linsitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — linsitinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for linsitinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sling Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSling Therapeutics, Inc.

linsitinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Thyroid Eye Disease2 trials

Trial1 trial

Metastatic Prostate Cancer1 trial

Cutaneous Squamous Cell Carcinoma1 trial

Small Cell Lung Cancer1 trial

Gastrointestinal Stromal Tumor1 trial

Ewing sarcoma1 trial

References

Drug Info

Quick Facts

Related News